Zynerba's cannabinoid formulations
GPTKB entity
Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:FA_Cup
|
| gptkbp:clinical_trial |
gptkb:Canada
gptkb:United_States Phase 2 improved quality of life positive outcomes reduced pain levels reduced seizure frequency reduced anxiety symptoms |
| gptkbp:collaborates_with |
research institutions
clinical research organizations |
| gptkbp:contains |
gptkb:cannabidiol_(CBD)
tetrahydrocannabinol (THC) |
| gptkbp:developed_by |
gptkb:Zynerba_Pharmaceuticals
|
| gptkbp:formulated_as |
gptkb:patches
topical gel |
| gptkbp:funding |
gptkb:venture_capital
government grants |
| gptkbp:future_prospects |
long-term effects
combination therapies patient-reported outcomes new formulations expanded indications |
| https://www.w3.org/2000/01/rdf-schema#label |
Zynerba's cannabinoid formulations
|
| gptkbp:invention |
patented
|
| gptkbp:investment_focus |
gptkb:Europe
gptkb:North_America |
| gptkbp:is_designed_to |
medical use
pediatric use adult use |
| gptkbp:marketed_as |
Zynerba brand
|
| gptkbp:patient_population |
patients with anxiety disorders
children with epilepsy adults with chronic pain |
| gptkbp:regulatory_approval_status |
under review
|
| gptkbp:research_focus |
therapeutic effects of cannabinoids
cannabinoid pharmacology |
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:shipping_options |
topical application
transdermal delivery |
| gptkbp:side_effect |
dizziness
nausea dry mouth mild sedation |
| gptkbp:used_for |
treatment of anxiety
treatment of epilepsy treatment of pain |
| gptkbp:bfsParent |
gptkb:Zynerba_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|